Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
Journal
Lung Cancer
Journal Volume
72
Journal Issue
2
Pages
205-212
Date Issued
2011
Author(s)
Wu J.-Y.
Hsu Y.-C.
Abstract
Introduction: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer (NSCLC). This study aimed to compare their clinical uses and the influence of EGFR mutation. Methods: The usages of erlotinib and gefitinib in advanced NSCLC were analyzed. Clinical data and EGFR mutational status of tumors were collected. Results: Seven hundred and sixteen (716) patients received gefitinib (n= 440) or erlotinib (n= 276) for stage IIIb or IV NSCLC. Erlotinib was prescribed more frequently than gefitinib in males (58.2% vs. 41.8%, p< 0.001), smokers (60.5% vs. 39.5%, p< 0.001), and non-adenocarcinoma (70.6% vs. 29.4%, p< 0.001). Of the 716 study patients, 327 underwent testing for EGFR mutations (170 with mutant EGFR and 157 with wild-type EGFR). Adenocarcinoma in patients with mutant EGFR and non-smoker status in patients with wild-type EGFR were associated with better overall survival after TK inhibitor treatment. In both patient groups with mutant EGFR or wild-type EGFR, the effectiveness of gefitinib and erlotinib, including drug response or overall survival, were not different. Conclusions: Our study revealed the obvious disparity in drug selection between erlotinib and gefitinib in clinical practice. Type of TK inhibitors did not influence treatment outcomes in patients with EGFR mutation or wild-type EGFR. ? 2010 Elsevier Ireland Ltd.
SDGs
Other Subjects
epidermal growth factor receptor; erlotinib; gefitinib; adult; advanced cancer; aged; article; cancer survival; drug efficacy; female; gene mutation; human; lung adenocarcinoma; lung non small cell cancer; major clinical study; male; overall survival; priority journal; smoking; treatment response; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis
Type
journal article